AgeneBio is dedicated to developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
Our mission is to discover and develop innovative therapeutics that preserve and restore brain function for patients at risk for neurodegeneration, to benefit the lives of those patients, their families, and society as a whole.
Our pipeline of novel therapies includes multiple candidates being evaluated in patients with neurological and psychiatric disease and is based on decades of research focused on cognitive neuroscience and the neurobiology of the aging brain. Our most advanced clinical program evaluates amnestic mild cognitive impairment due to Alzheimer’s disease (MCI due to AD), the symptomatic, pre-dementia stage of Alzheimer’s. Currently there are no FDA approved treatments for this condition. The HOPE4MCI program with AGB101 uses a protocol agreed to by the FDA for pivotal Phase 3 testing now in an ongoing Phase 2b trial.
AGB101 |
Our lead asset, in late stage clinical development, is being evaluated for the treatment of MCI due to AD. |
Discovery: GABAA α5 positive allosteric modulators |
Our novel late-stage discovery program is evaluating a spectrum of neurological and psychiatric conditions including MCI due to AD and schizophrenia. |
These investigational compounds are not approved by the FDA. The safety and efficacy have not been established.
Decades of Research Support Our Pipeline
Research shows that overactivity in key brain circuits contributes to cognitive impairment and drives neurodegeneration.